Author Archives: Darren Marchal

EIA Data Reintroduces Natural Gas Volatility

After a period of very slow trading, the prompt month natural gas contract saw a trading range of 11.1 cents today, its largest since February 21st. Trading ranges had been historically low recently as the market coiled, with today’s move now fitting right in with past years.  Prices initially traded lower only to then shoot…

What The EPS? EM Vs. DM Earnings Outlook

This week we look at the earnings outlook for emerging markets (EM) and developed markets (DM) – on both fronts I am specifically using the MSCI indexes, i.e. the MSCI Emerging Markets Index, and the MSCI World Index (as distinct from the MSCI ACWI). For the consensus earnings estimates I am using the Thomson Reuters…

Japanese Yen: Safe Haven Or Inflation Proxy?

In our last commentary on the Japanese yen, we wrote that the currency was looking excessively weak against the euro. In particular, we stated that bullish catalysts driving EUR/JPY were at risk as speculator positioning in both long euro and short yen trades were looking extreme. In addition, we flagged changes to the Bank of Japan’s…

Short-Term Uptrend Is Doing Well

The relative strength of Commodities and Currencies favors higher stock prices. The Short and Medium-Term Trends The short-term uptrend is doing well, and I believe a new medium-term uptrend has started. Breadth indicators continue to support the uptrend. New highs are starting to look healthy, and new lows are at harmless levels. The Bullish Percents…

Nvidia (NVDA) Crushes Q1 Earnings Estimates, Revenue Surges 66%

Nvidia Corporation (NVDA – Free Report) just released its latest quarterly financial results, posting non-GAAP earnings of $2.05 per share and revenues of $3.21 billion. Currently, NVDA is a Zacks Rank #3 (Hold), but that could change based on today’s results. Shares of the company have gained about 13% over the past month, including a 1.7% gain during…

The Ceaseless Ascent

I’d like to off the following off-the-wall musings as a very different take on the market. It’s a disposition that many, many people share, and perhaps it would help me get in sync with the rest of the planet to actually type what everyone else is thinking. I type this to be neither facetious nor…

Biotech Stocks Underperform Market: CELG, EXEL, PBYI, XBI

Biotechs Underperform and Lag Market Indices on a Good Day-NASDAQ up 0.89% Trading Range Requires Good Stock Picking Skills, XBI is down 0.85% to $89.04. Stealth Buyout with Lilly Acquisition of ARMO BioSciences Biotechs underperformed despite a good opening with the XBI trying to break through the SMA 50 level but fell back around mid-day. Some good news helped…